Next Article in Journal
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights
Previous Article in Journal
Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis
 
 
Correction

Article Versions Notes

Cancers 2024, 16(19), 3258; https://doi.org/10.3390/cancers16193258
Action Date Notes Link
article xml file uploaded 25 September 2024 07:39 CEST Original file -
article xml uploaded. 25 September 2024 07:39 CEST Update -
article pdf uploaded. 25 September 2024 07:39 CEST Version of Record https://www.mdpi.com/2072-6694/16/19/3258/pdf-vor
article html file updated 25 September 2024 07:40 CEST Original file -
article xml file uploaded 25 September 2024 07:50 CEST Update -
article xml uploaded. 25 September 2024 07:50 CEST Update -
article pdf uploaded. 25 September 2024 07:50 CEST Updated version of record https://www.mdpi.com/2072-6694/16/19/3258/pdf-vor
article html file updated 25 September 2024 07:52 CEST Update -
article xml file uploaded 25 September 2024 08:07 CEST Update -
article xml uploaded. 25 September 2024 08:07 CEST Update -
article pdf uploaded. 25 September 2024 08:07 CEST Updated version of record https://www.mdpi.com/2072-6694/16/19/3258/pdf-vor
article html file updated 25 September 2024 08:10 CEST Update -
article xml file uploaded 8 October 2024 09:37 CEST Update -
article xml uploaded. 8 October 2024 09:37 CEST Update https://www.mdpi.com/2072-6694/16/19/3258/xml
article pdf uploaded. 8 October 2024 09:37 CEST Updated version of record https://www.mdpi.com/2072-6694/16/19/3258/pdf
article html file updated 8 October 2024 09:39 CEST Update https://www.mdpi.com/2072-6694/16/19/3258/html
Back to TopTop